Watch Integrum AB Series B for free: we tell you when fair value or trend changes.

Integrum AB Series B (INTEG-B) fair value: what the stock is really worth

As of Oct 19, 2026: fair value (intrinsic value) of Integrum AB Series B stock SEK 1.70, price SEK 8.97, upside -81.0%, quality 27 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · SE · ISIN SE0009807266

Thin data Oct 3, 2026

Integrum AB Series B

INTEG-B · ST

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 81% below what the stock costs today.

Low debt

Expensive Growth (revenue 5y +16.2 %/yr in SEK)

Mixed vs. peers (4/10)

Fair value kr 1.70 · Strongly overvalued (−81.0%)

Quality 27/100

Loss-making · -36.3% net margin (TTM)

Negative free cash flow

Narrow moat 11/100

Thin data

⚠ Dilution

26 models, one by oneBear kr 1.12 to bull kr 2.13 Growth analysisrevenue history, year by year Quality 27/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Integrum AB Series B for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range kr 6.96 – kr 102.00 · fair‑value band kr 1.12 – kr 2.13 · the kr 8.97 price screens above the kr 1.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow Integrum AB Series B in your weekly email

Every Wednesday you see whether Integrum AB Series B is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses.

Show moreShow less

The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket.

The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. It also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation.

It sells its implant systems to hospitals, clinics, and orthopedists worldwide. The company was incorporated in 1990 and is headquartered in Mölndal, Sweden.

Stock analysis

Integrum AB Series B (INTEG-B) currently trades at kr 8.97, while our model-based Fair Value estimate is kr 1.70, 81.0% below the price, so the stock looks overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: kr 1.12 (bear) to kr 2.13 (bull), the price of kr 8.97 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Integrum AB Series B reported revenue of 91.4M SEK in FY2025 versus 55.7M SEK in FY2021, a compound +13.2%/yr. Reported net income was −46.3M SEK in FY2025.

Key figures

Market cap 239M SEK (≈ $24.1M) Micro · P/S ratio 2.44 · EPS (TTM) kr −1.42 · Net margin −36.3% · Return on equity −20.8% · Return on assets (EBIT) −10.7% · Operating margin 7.4% · Revenue (TTM) 97.9M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 11 out of 100 (medium confidence).

What moves the price

The share trades about 24% below its 52-week high and 29% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −81%, INTEG-B screens richer than that median.

Fair Value models

Bear kr 1.12 Fair Value kr 1.70 Bull kr 2.13

Price kr 8.97 · Upside -81.0%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

NCAV (Graham) kr 1.32 kr 2.00 kr 2.50 54

All 1 models by family

Asset-Based

NCAV (Graham) kr 1.32 kr 2.00 kr 2.50 54

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5

How much profit the company makes from its sales and capital

Quality Growth 15

Are margins and returns getting better?

Cashflow 9

Do the profits arrive as real cash?

Financial strength 83

Debt, balance sheet and risk of trouble

Investment 44

Does it invest with discipline instead of growing at any price?

Low Volatility 52

How calm the share price moves, does not count

Momentum 41

Price trend of the last 3 to 12 months, does not count

Near the 52-week high 24

Distance to the 52-week high, does not count

New shares 0

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100

The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Revenue growth 1 year

+0.3%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.2%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+16.2%

Start year 2020 (pandemic). Over 10 years: +22.2% a year

Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+14.0%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−4.3% (2020) → −56.4% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

INTEG-B screens overvalued: fair value 81% below the price. Compare with Abbott Laboratories, →

Compare Integrum AB Series B with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks

Beats the industry median on 3/8 measures

Overall it trails its industry peers.

Valuation

Quality Score 27 · Bottom 25%

Fair Value upside −81.0% · Bottom 25%

Profitability

Return on assets −22.8% · Bottom 25%

Net margin (12 months) −36.3% · Bottom 25%

Operating margin (12 months) 7.4% · Below median

Growth and dividend

Revenue growth (quarter YoY) 27.2% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.39× · Cheaper than median

P/S (12 months) 2.44× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 10

FUTURE (revenue growth)100 · sector 33

PAST (return on equity)0 · sector 16

HEALTH (low debt)100 · sector 98

DIVIDEND (yield)0 · sector 37

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Stryker Corporation SYK	$282.60	$310.86	+10%	vs INTEG-B
Boston Scientific Corporation BSX	$43.00	$47.30	+10%	vs INTEG-B
DexCom, Inc DXCM	$84.11	$92.52	+10%	vs INTEG-B
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥166.00	¥182.60	+10%	vs INTEG-B
GE HealthCare Technologies Inc GEHC	$65.74	$70.37	+7%	vs INTEG-B
Edwards Lifesciences Corporation EW	$86.60	$81.94	−5%	vs INTEG-B
Siemens Healthineers AG SHL	€41.45	€35.19	−15%	vs INTEG-B
Abbott Laboratories, ABT	$102.61	$74.79	−27%	vs INTEG-B
Medtronic plc MDT	$91.93	$65.61	−29%	vs INTEG-B
Koninklijke Philips N.V PHIA	€22.18	€15.23	−31%	vs INTEG-B

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Integrum AB Series B · Fair Value
kr 1.70 −81%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/INTEG-B" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Integrum AB Series B · Fair Value</span><br><b style="font-size:20px">kr 1.70</b> <span style="color:var(--red);font-weight:700;font-size:14px">−81%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Integrum AB Series B Fair Value". https://www.fairvalue-calculator.com/stock/INTEG-B

Frequently asked questions

Is Integrum AB Series B (INTEG-B) overvalued or undervalued?

As of Oct 3, 2026, our model estimates a fair value of kr 1.70 versus a price of kr 8.97, about −81% upside (overvalued).

What is the fair value of INTEG-B?

Our model-based fair value for Integrum AB Series B is kr 1.70 (as of Oct 3, 2026), built from audited fundamentals. The current price: kr 8.97.

What is the quality score of INTEG-B?

Integrum AB Series B has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Integrum AB Series B (INTEG-B)?

Our model-based price target is the fair value of kr 1.70 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario kr 1.12, optimistic scenario kr 2.13. It is a calculation from audited fundamentals, not an analyst target.

What is the Integrum AB Series B stock forecast for 2026?

Our models put fair value at kr 1.70, about −81% upside versus a price of kr 8.97 (overvalued). Cautious scenario kr 1.12, optimistic scenario kr 2.13. The calculation is refreshed regularly with new filings.

What is the revenue of Integrum AB Series B (INTEG-B)?

Integrum AB Series B reported trailing-twelve-month revenue of about 97.9M SEK (latest available figure, as of Oct 3, 2026).

What is the intrinsic value of Integrum AB Series B (INTEG-B)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Integrum AB Series B it is kr 1.70 per share (as of Oct 3, 2026), against a price of kr 8.97. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Integrum AB Series B stock overvalued or undervalued in 2026?

As of Oct 3, 2026, INTEG-B trades above its calculated fair value: price kr 8.97, fair value kr 1.70, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of INTEG-B?

No. The price is what the market pays today (kr 8.97); the fair value is what the company's own numbers justify (kr 1.70). For Integrum AB Series B the two are kr 7.27 per share apart. That gap is exactly why we show both numbers side by side.

How much is Integrum AB Series B worth?

The market values Integrum AB Series B at about 239M SEK (market capitalisation, as of Oct 3, 2026). Per share that is kr 8.97; our models calculate a fair value of kr 1.70 per share.

What do the bullish and bearish scenarios say about INTEG-B?

Our models span a range for Integrum AB Series B: cautious scenario kr 1.12, base kr 1.70, optimistic kr 2.13 per share (as of Oct 3, 2026, price kr 8.97). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Integrum AB Series B (INTEG-B)?

Balance-sheet figures for Integrum AB Series B (as of Oct 3, 2026): return on equity −20.8%. They feed the Quality Score of 27/100, which measures business quality independently of the share price.

How far is INTEG-B from its 52-week high?

Integrum AB Series B trades at kr 8.97, about 24% below its 52-week high of kr 11.80 and 29% above the low of kr 6.96 (as of Oct 19, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.70 is for.

Which stocks are comparable to Integrum AB Series B?

From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Integrum AB Series B stock attractive at the current price?

The data as of Oct 3, 2026: price kr 8.97, calculated fair value kr 1.70 (−81%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of INTEG-B calculated?

We run Integrum AB Series B through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 1.70, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.9 % above its aggregate fair value. Integrum AB Series B itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Integrum AB Series B (INTEG-B)?

The closing price on Oct 19, 2026 was kr 8.97. Our model-based fair value is kr 1.70, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Integrum AB Series B right now?

The price sits above even our optimistic bull case (kr 2.13). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 1.12 to kr 2.13) leaves room in how you read the outcome.

Key figures of Integrum AB Series B

How large is the market capitalisation of Integrum AB Series B (INTEG-B)?

The market capitalisation of Integrum AB Series B is 239M SEK (≈ $24.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Integrum AB Series B (INTEG-B)?

The price-to-sales ratio of Integrum AB Series B is 2.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Integrum AB Series B (INTEG-B)?

Earnings per share at Integrum AB Series B are kr −1.42. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Integrum AB Series B (INTEG-B)?

The net margin of Integrum AB Series B is −36.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Integrum AB Series B (INTEG-B)?

The return on equity (ROE) of Integrum AB Series B is −20.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Integrum AB Series B (INTEG-B)?

On an EBIT basis the return on assets of Integrum AB Series B is −10.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Integrum AB Series B (INTEG-B)?

The operating margin of Integrum AB Series B is 7.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Integrum AB Series B (INTEG-B)?

Revenue at Integrum AB Series B is growing +27.2% versus a year earlier (3y avg +7.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Integrum AB Series B (INTEG-B)?

Earnings per share at Integrum AB Series B are growing +61.5% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Integrum AB Series B (INTEG-B) generate?

The free cash flow of Integrum AB Series B is −58.0M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Integrum AB Series B (INTEG-B) hold?

Integrum AB Series B holds more cash than debt, 15.9M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Integrum AB Series B in the live analysis

One click puts Integrum AB Series B on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.